Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Important paper from Japan published in Blood.
The authors have developed FVIII variants with increased specific activity, which can potentially be used for gene therapy in hemophilia A.
These would be the equivalent of the Padua variant for FIX and can be used at much lower doses.
Even when used at 1/30th of the dose of Roctavian in macaques, supraphysiological FVIII levels were achieved.
No human studies yet.”
Read the full article here.
Article: Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Authors: Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J. S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 23, 2026, 07:28Isabelle Grenier-Pleau: Targeting Von Willebrand Disease to Transform Women’s Health
-
Sep 23, 2026, 07:07Wolfgang Miesbach: Mechanisms of Liver Injury After Hemophilia A Gene Therapy
-
Sep 23, 2026, 06:24Nicolas Gendron: Everolimus and Venous Thromboembolic Risk in Kidney Transplantation
-
Sep 23, 2026, 06:07Hoori Shahwar: Cerebral Venous Sinus Thrombosis Diagnosis and Management
-
Sep 23, 2026, 06:06Advancing Hemophilia Care and Patient Advocacy in Bangladesh – World Federation of Hemophilia
-
Sep 23, 2026, 05:54Bringing the Global Thrombosis and Haemostasis Community Together in 2027 – ISTH
-
Sep 23, 2026, 04:34David Akande: When Sickle Cell Crises Have No Clear Trigger
-
Sep 23, 2026, 04:13Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT
-
Sep 23, 2026, 04:09Beth Psaila: Applications Now Open for the Gordon Research Conference on Megakaryocytes and Platelets